NCT01828112 2025-02-07LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibNovartisPhase 3 Completed231 enrolled 33 charts
NCT01828099 2025-01-16LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerNovartisPhase 3 Completed376 enrolled 34 charts 1 FDA
NCT04452214 2023-07-14A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCantargia ABPhase 1 Completed19 enrolled
NCT04861948 2022-10-04IBI188 Combination Therapy in Solid TumorsInnovent Biologics (Suzhou) Co. Ltd.Phase 1 Terminated9 enrolled
NCT01218516 2020-08-20A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the LungMorphotekPhase 2 Completed130 enrolled 11 charts
NCT01646125 2019-07-24An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR MutationsNovartisPhase 2 Terminated59 enrolled 9 charts